SCHEMBL243363

SCHEMBL243363

COC([C]=O)CCC[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL246094 0.91
SCHEMBL7377390 0.91
SCHEMBL5965378 0.91
SCHEMBL6373455 0.86
SCHEMBL9481280 0.81
SCHEMBL8740756 0.80 THRB (0.31)
SCHEMBL9479472 0.79 ZDHHC7 (0.39)
SCHEMBL4048541 0.78
SCHEMBL7340986 0.77 ZDHHC7 (0.42)
SCHEMBL11118483 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070172517-A1 Compositions capable of facilitation penetration across a biological barrier CHIASMA, INC. 2007-07-26 US claimed
US-7094758-B2 Apoptotic compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-08-22 US claimed
EP-1670500-A2 COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER Chiasma, Ltd. (IL) 2006-06-21 EP claimed
US-7041784-B2 Procaspase-3 activation; peptide comprising AX1 wherein X1 is V, I or L (alanine with valine, isoleucine or leucine) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2006-05-09 US claimed
US-20060084611-A1 Apoptotic compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2006-04-20 US claimed
WO-2005094785-A2 COMPOSITIONS CAPABLE OF FACILITATING PENETRATION ACROSS A BIOLOGICAL BARRIER CHIASMA, LTD. (IL) 2005-10-13 WO claimed
US-20050136103-A1 Transepithelial delivery of effectorsequentially coupled with a counter ion to the at least one effector and at least one pharmaceutically acceptable hydrophobic agent; translocation, encapsulation CHIASMA, INC. 2005-06-23 US claimed
US-20040146549-A1 Amino acid sequences capable of facilitating penetration across a biological barrier CHIASMA, INC. 2004-07-29 US claimed
US-6608026-B1 Contacting pathogenic cells with AV peptoid which comprises amino acid sequence Ala-Val-Pro, is fewer than 20 residues in length, has molecular weight less than 1000, and interacts with Inhibitor of Apoptosis protein, to enhance apoptosis BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-19 US claimed
US-12023316-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-07-02 US disclosed
US-11925655-B2 FAP-activated therapeutic agents, and uses related thereto BACH BIOSCIENCES, LLC (US) 2024-03-12 US disclosed
US-20240025949-A1 Beta-Arrestin Effectors and Compositions and Methods of Use Thereof TREVENA, INC. 2024-01-25 US disclosed
EP-4299134-A2 FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO Bach Biosciences, LLC (US) 2024-01-03 EP disclosed
EP-4262878-A1 FAP-ACTIVATED RADIOTHERANOSTICS, AND USES RELATED THERETO TRUSTEES OF TUFTS COLLEGE (US) 2023-10-25 EP disclosed
WO-1994025491-A1 FIBRIN-TARGETED INHIBITORS OF THROMBIN PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1994-11-10 WO disclosed
WO-1994018832-A1 CD4 MEDIATED MODULATION OF LIPID KINASES DANA-FARBER CANCER INSTITUTE, INC. (US) 1994-09-01 WO disclosed
WO-1994019002-A1 REGULATOR REGIONS OF G PROTEINS THE GENERAL HOSPITAL CORPORATION (US) 1994-09-01 WO disclosed
EP-0518955-A4 CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS 1993-09-22 EP disclosed
EP-0518955-A1 CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS CEPHALON, INC. (US) 1992-12-23 EP disclosed
WO-1991013904-A1 CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS CEPHALON, INC. (US) 1991-09-19 WO disclosed